NCT06214052 - VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 7, 2024

Primary Completion Date

June 12, 2024

Study Completion Date

June 12, 2024

Conditions

HIV Infections

Interventions

DRUG

VH4524184

VH4524184 was administered as tablets orally at Day 1.

DRUG

Matching Placebo

VH4524184 Matching Placebo was administered as tablets orally at Day 1.

DRUG

Antiretroviral therapy

Antiretroviral therapy was administered as available and as per investigator's recommendation.

Trial Locations (17)

20162

GSK Investigational Site, Milan

28020

GSK Investigational Site, Madrid

30003

GSK Investigational Site, Murcia

32720

GSK Investigational Site, DeLand

32803

GSK Investigational Site, Orlando

46026

GSK Investigational Site, Valencia

90027

GSK Investigational Site, Los Angeles

90046

GSK Investigational Site, West Hollywood

93301

GSK Investigational Site, Bakersfield

C1202

GSK Investigational Site, Buenos Aires

C1425AGC

GSK Investigational Site, Buenos Aires

C1405CKC

GSK Investigational Site, Ciudad Autonoma de Bueno

H4A 3J1

GSK Investigational Site, Montreal

G1V 4G2

GSK Investigational Site, Québec

08003

GSK Investigational Site, Barcelona

08026

GSK Investigational Site, Barcelona

03203

GSK Investigational Site, Elche Alicante